drugset / Trial / NCT03900793
Losartan + Sunitinib in Treatment of Osteosarcoma
Phase 1
Recruiting
41 enrolled
University of Colorado, Denver
Cancer League of Colorado · collabColorado State University · collabSwim Across America · collab
NaSequentialOpen-labelTreatment
Summary
This study is a Phase 1/1b clinical trial that aims to determine the Maximally Tolerated Dose of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose Escalation phase of the study, using a 3+3 design. Medication dosages will increase until a maximally tolerated dose is found. Patients will then be accrued to the Dose Expansion phase of the trial, where efficacy of pre-determined dose will be preliminarily assessed.
Timeline
- Start
- 2019-08-26
- Primary completion
- 2027-08-01
- Completion
- 2029-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Losartan | Other / unclassified | 50 mg | Oral |
| Subject | Losartan | Other / unclassified | 75 mg | Oral |
| Subject | Losartan | Other / unclassified | 100 mg | Oral |
| Subject | Sunitinib | Small molecule | — | Oral |